Joint Diseases (Joint Disease)

05/01/2002 - "Infliximab appears to be effective and well tolerated for both axial and peripheral joint disease in AS even at lower doses than those examined to date. "
07/01/2006 - "Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment."
06/01/2007 - "Patients with active chronic inflammatory joint disease were introduced into the infliximab therapy programme. "
06/01/2007 - "To evaluate infliximab effect on oxidative stress in active chronic inflammatory joint disease. "
06/01/2007 - "The effect of infliximab on oxidative stress in chronic inflammatory joint disease."

01/01/2004 - "A topical 1% diclofenac liposomal cream proved to be safe, easy to use, and effective in reducing equine lameness caused by degenerative joint disease. "
05/01/1991 - "Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease."
01/01/1992 - "In conclusion, the results of the present study indicate that 600 mg etodolac SR once daily for 4 weeks is effective in the treatment of patients with degenerative joint disease of the knee, as is 100 mg diclofenac SR. In addition, both drugs have comparable tolerability profiles."
04/01/1999 - "Comparison of therapeutic efficacy of nimesulide and diclofenac in patients with degenerative joint diseases."
04/01/2003 - "Diclofenac suppositories in the treatment of bone and joint diseases. "

11/01/1991 - "The determination and characterization of cytokines and their inhibitors in body fluids and tissues may contribute to a better understanding of the basic mechanisms of the pathogenesis of inflammatory joint diseases, and may help to develop better modalities of therapy. "
01/01/2013 - "Previous studies have shown that some cytokines have protective effects on cartilage in joint diseases. "
01/01/2008 - "Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases."
12/01/2004 - "These findings indicate that pro-inflammatory cytokines can modulate the responses of meniscal cells to mechanical signals, suggesting that both biomechanical and inflammatory factors could contribute to the progression of joint disease as a consequence of altered loading of the meniscus."
05/01/2003 - "Osteoclasts and osteoclastogenic factors such as inflammatory cytokines and RANK-L are present within inflamed joints, and osteoclastic bone resorptive activities are also displayed, further suggesting the possibility that osteoclasts are responsible for the joint cartilage and bone matrix damage observed in this joint disease."

09/01/2006 - "Development of an H1 antagonist that inhibits the release of IL-6 from synoviocytes may be beneficial for the treatment of inflammatory joint disease."
07/01/2009 - "Dyslipidaemia is a feature of inflammatory joint diseases and is closely related to elevated CRP and Il-6 levels. "
01/31/2003 - "These IL-6 effects might contribute to the phenotype loss of chondrocytes in joint diseases and the alteration of articular cartilage associated with this pathology."
11/01/2001 - "IL-6 was the most sensitive and specific for joint disease and could be an excellent screening test for the presence of joint disease when lameness is difficult to identify or is intermittent. "
11/01/2001 - "Any IL-6 in synovial fluid indicated joint disease and correlated highly with synovial fluid white blood cell count (P <.0001). "

01/01/2014 - "Tumor necrosis factor-α (TNF-α) plays an essential role in the regulation of bone homeostasis in several chronic immune and inflammatory joint diseases, where inhibition of TNF has led to significant clinical improvement. "
12/01/2006 - "TNFalpha antagonists are effective in the treatment of chronic inflammatory joint disease. "
01/05/2010 - "These studies revealed the important role of TLR4 signaling in MPS bone and joint disease and suggest that targeting TNF-alpha may have positive therapeutic effects."
10/01/2013 - "Tumor necrosis factor inhibition modulates thrombospondin-1 expression in human inflammatory joint disease through altered NR4A2 activity."
05/11/2012 - "Tumor necrosis factor α (TNF-α) is a pleiotropic cytokine mediating inflammatory as well as cell death activities, and is thought to induce chondrocytic chondrolysis in inflammatory and degenerative joint diseases. "

01/01/2015 - "The primary outcome was remission (28 joint disease activity score calculated with C-reactive protein <2.6) at W16 (intention-to-treat analysis). "
02/01/2014 - "Patients with RA in clinical remission [28-joint Disease Activity Score-C-reactive protein (DAS28-CRP) < 2.6, n = 185] or LDA state (2.6 ≤ DAS28-CRP < 3.2, n = 69) with longitudinal MRI and radiographic data were included from 5 cohorts (4 international centers). "
03/01/2005 - "The aim of our study was to investigate if there is an increase in serum levels of C-reactive protein (CRP) in degenerative joint disease (DJD) and if CRP could be used to help diagnose OA. "
09/01/2015 - "Serum and synovial fluid C-reactive protein level variations in dogs with degenerative joint disease and their relationships with physiological parameters."
09/01/2013 - "Clinical, functional, and radiographic outcomes were assessed using composite measures of disease activity (e.g., American College of Rheumatology responses, 28-joint Disease Activity Score with C-reactive protein, Simplified Disease Activity Index), Health Assessment Questionnaire-Disability Index, and the modified total Sharp score (mTSS), respectively. "

05/01/2006 - "To compare 28 joint disease activity score (DAS28) remission with comprehensive joint count DAS remission in rheumatoid arthritis. "
01/01/2006 - "Four steps were employed: (1) review of published reports on DMARD efficacy against rheumatoid arthritis; (2) inventory of the information available to guide DMARD choice; (3) selection of the most pertinent information by 12 experts using a Delphi method; and (4) choice of DMARDs in 12 clinical situations defined by items selected in step 3 (28 joint disease activity score (DAS 28): < or =3.2; >3.2 and < or =5.1; >5.1; rheumatoid factor status (positive/negative); structural damage (with/without)-that is, 3 x 2 x 2). "
01/01/2011 - "With an overall high grade of evidence this review revealed an improvement of clinical results (ACR50, 28 joint disease activity score (DAS-28) remission and HAQ scores) with certolizumab pegol. Adverse events were more frequent with certolizumab; there was a statistically significant increase in the number of serious adverse events, infections and hypertension."

09/01/2009 - "Low quality of evidence for glucosamine-based nutraceuticals in equine joint disease: review of in vivo studies."
06/01/2014 - "The role of 99mTc-labelled glucosamine (99mTc-ECDG) in the evaluation of rheumatic joint disease: a screening experience."
09/01/2008 - "Glucosamine may have use at clinically relevant concentrations in the treatment of inflammatory joint disease."
03/01/2001 - "Many patients with degenerative joint disease use glucosamine sulfate. "
03/01/2001 - "Another drug widely used in the treatment of degenerative joint disease is glucosamine sulfate. "

04/01/2004 - "Hyaluronic acid minimally effective for knee degenerative joint disease."
01/01/2011 - "The properties of hyaluronic acid used for treatment of acute and chronic joint disease are known for many years and this compound is widely used both in humans and animals. "
05/04/2007 - "Our data showed the protective effect of the extracts of Opuntia ficus indica cladodes in cartilage alteration, which appears greater than that elicited by hyaluronic acid (HA) commonly employed as visco-supplementation in the treatment of joint diseases."
07/01/2006 - "Oral preparations of hyaluronan are being used to treat joint disease in horse. "
09/01/2004 - "Hyaluronic acid (HA) is an endogenous glycosaminoglycan used in the treatment of joint diseases, but medication control is required by horseracing authorities. "

07/01/2006 - "Our data showed the protective effects of JW-E in cartilage alteration, that appears greater than that elicited by indomethacin, a not steroidal antiinflammatory drug (NSAID), commonly employed in joint diseases."
09/01/1981 - "1. Twelve treated hypertensive patients (ages 58-71 years) who had also been treated for joint disease participated in a randomized double-blind crossover placebo-controlled study to investigate the effects of indomethacin (25 mg three times daily) on blood pressure and biochemical parameters over a 6-week period. "
09/30/2005 - "This protection appeared to be greater than that elicited by indomethacin, which is usually employed in joint diseases. "
12/15/1978 - "[Comparison of indomethacin-retard and indomethacin for degenerative joint diseases--a double-blind study]."
01/01/1970 - "[Experience in the therapeutic use of indocid in chronic joint diseases]."

12/01/2011 - "Total knee arthroplasty (TKA) has been proven to be the most effective treatment for patients with severe joint disease. "
09/01/2010 - "Total joint arthroplasties are recognized as being effective in the treatment of joint disease and making a significant difference in patients' quality of life. "
10/01/1982 - "Total hip arthroplasty should not be recommended for the young patient who has one or two joint diseases and no limiting systemic factors, with the expectation that when the total hip fails, it can be converted to a resection arthroplasty and the patient improved as compared with the pre-total hip status. "
04/01/2015 - "Studies on patients with degenerative joint disease of the hip show that femoral periprosthetic bone mineral decreases following total hip arthroplasty. "
10/01/2014 - "The purpose of this study was to review the results of patellofemoral arthroplasty (PFA) performed by a single surgeon at a single institution in order to determine factors associated with clinical outcomes and progression of tibiofemoral degenerative joint disease. "

04/01/1985 - "Alleviation of joint disease activity was significantly greater in the high-dose group as judged by morning stiffness, joint tenderness, and functional assessment (global composite score) at 3 and 6 months after radiotherapy. "
01/08/2010 - "Radiotherapy is increasingly used in the treatment of joint diseases, but limited information is available on the effects of radiation on cartilage. "
06/01/1999 - "Radiotherapy with total doses of < or =6 Gy has been given as very effective and low risk treatment of painful degenerative joint diseases and other inflammatory processes. "
08/20/1995 - "[Radiotherapy of degenerative inflammatory joint diseases in the elderly. "
04/01/1982 - "Compared with other therapeutic methods, the long term results or radiotherapy of degenerative joint diseases are generally favorable. "

08/01/2015 - "The aim of this study was to determine whether single-photon emission computed tomography combined with conventional computed tomography (SPECT-CT) could be used to localize the site of degenerative joint disease for intra-articular injection and thereby improve the clinical success of the procedure. "
01/01/2006 - "Radiosynoviorthesis using intraarticular injection of beta-emitting radiocolloids is increasingly performed throughout Europe in patients with inflammatory joint disease. "
12/01/2005 - "Intra-articular injections for joint disease in horses."
04/01/1990 - "Intra-articular injection techniques and medications are discussed because of the frequency of joint disease. "
10/01/2010 - "Risk factors were consistently identified and included intravenous substance abuse, prior joint disease, a recent history of intraarticular injections, and a remote history of surgery. "

03/31/1973 - "[Balneotherapy of inflammatory and degenerative joint diseases]."
03/01/1967 - "[The possibilites of physical therapy of inflammatory joint diseases including balneotherapy]."
05/01/2008 - "Balneotherapy is an established treatment modality for musculoskeletal disease, but few studies have examined the efficacy of spa therapy in elderly patients with degenerative spine and joint diseases. "

05/01/1998 - "Specific aims included documenting the time of and extent of improved limb function as measured by force plate analysis, evaluating the progression of degenerative joint disease (DJD) in the treated and untreated coxofemoral joints, and determining whether or not triple pelvic osteotomy resulted in degenerative joint changes in the ipsilateral stifle and hock. "
09/01/2013 - "Supramalleolar osteotomies for degenerative joint disease of the ankle joint: indication, technique and results."
03/01/2013 - "Periarticular osteotomies for degenerative joint disease of the knee."
02/01/2012 - "Triple pelvic osteotomy (TPO) is one of the surgical procedures for use to try to reduce subsequent degenerative joint disease or modify the progress of hip dysplasia in young dogs. "
10/01/2008 - "Corrective osteotomy may be a reasonable option for proximal humeral malunions in young patients without evidence of degenerative joint disease. "